KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study. PMID 41854792 · Breast Cancer Res Treat · 2026-Mar-19 The record is an original report of a randomized trial in oncology with time-to-event endpoints and drug interventions. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (abstract, publication types, mesh terms). The deterministic review correctly identifies the phase evidence as unclear. Therefore, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Long-term protection of an inactivated enterovirus type 71 vaccine against hand, foot, and mouth diseases in children: a modelling study. PMID 41650673 · Vaccine · 2026-Mar-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II/III clinical trial. PMID 41317338 · Br J Dermatol · 2026-Mar-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cluster randomised controlled trial for service delivery redesign of primary care for people with diabetes: study protocol. PMID 41857847 · BMJ Open · 2026-Mar-18 方案论文未报告临床试验结果。
H L
旧查询独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Superior efficacy and comparable safety of calcipotriol plus betamethasone dipropionate foam vs. ointment in Chinese patients with plaque psoriasis: A randomized phase 3 trial. PMID 41850772 · Chin Med J (Engl) · 2026-Mar-17 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Identification of tofersen PD-response biomarkers in VALOR clinical trial CSF via multiplexed quantitative proteomics. PMID 41850233 · Cell Rep Med · 2026-Mar-17 The study is a Phase III randomized trial of a drug (tofersen) in humans, but it is not an oncology study (ALS is a neurodegenerative disease). Furthermore, the primary analysis is a pharmacodynamic biomarker study (proteomics), not a time-to-event efficacy endpoint (OS, PFS, etc.) report.
H L
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment guided by cerebral oximetry in newborns receiving invasive mechanical ventilation: study protocol for step one of the SafeBoosC-IIIv randomised clinical trial. PMID 41845443 · Trials · 2026-Mar-17 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
"Having surgery is necessary" - a qualitative analysis of the experiences of frail older adults treated with, and recovering from colorectal cancer surgery. PMID 41845272 · BMC Geriatr · 2026-Mar-17 This is a qualitative analysis of patient experiences from the control group of a randomized trial. It does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) and lacks a drug-containing intervention. The publication type is 'Journal Article' with 'Randomized Controlled Trial' but the content is qualitative, not a primary/secondary efficacy result.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of concurrent hyperbaric oxygen therapy with chemoradiotherapy for glioma: a meta-analysis. PMID 41843266 · Clin Transl Oncol · 2026-Mar-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures. PMID 41843046 · Int J Clin Pharm · 2026-Mar-17 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Integrated psychological resilience and nutritional support improves sleep, emotional wellbeing, inflammation, and clinical recovery in colon cancer: a randomized controlled trial. PMID 41841224 · Psychol Health Med · 2026-Mar-17 The study is an oncology RCT with time-to-event endpoints, but it fails the drug intervention criterion (intervention is non-drug). The phase is also not definitively established as Phase III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Platinum-free triplet therapy with nab-paclitaxel, S-1, and tislelizumab as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma: a phase ii single-arm trial. PMID 41840368 · BMC Cancer · 2026-Mar-17 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 10 Panel · risk visible
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial. PMID 41759531 · Cell Rep Med · 2026-Mar-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The effects of a smoking cessation intervention on mortality after a 32.5-year follow-up period: a randomized clinical trial. PMID 41164942 · Am J Epidemiol · 2026-Mar-17 Study is a randomized clinical trial with time-to-event mortality endpoints, but it is a smoking cessation intervention trial (non-drug) and does not provide evidence of being a Phase III/IIIb or Phase II/III oncology trial. The primary intervention is behavioral (smoking cessation program) with bronchodilator/placebo arms, but the drug component (bronchodilator) is not the primary intervention and the trial is not focused on a drug-containing oncology treatment.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men. PMID 41162330 · Clin Infect Dis · 2026-Mar-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment. PMID 41128642 · J Clin Endocrinol Metab · 2026-Mar-17 The study is a Phase III randomized trial of a drug for acromegaly, which is not a human malignant neoplasm. The primary efficacy endpoint is a biochemical response (IGF-I normalization), not a time-to-event endpoint like OS, PFS, or DFS, and there is no indication of Kaplan-Meier analysis or hazard ratios for survival/time-to-event data.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among Women Living with HIV in South Africa: Primary Outcomes from the ACT 2 Randomized Trial. PMID 41891028 · medRxiv · 2026-Mar-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial. PMID 41839514 · BMJ · 2026-Mar-16 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 4 Figure · 4 Panel · risk unclear
A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer. PMID 41528981 · Clin Cancer Res · 2026-Mar-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. PMID 41427951 · Clin Cancer Res · 2026-Mar-16 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 8 Panel · risk visible
Valued Living intervention to increase advance care planning and well-being in depressed and anxious adults with advanced cancer: Randomized trial in community oncology clinics. PMID 41848105 · Cancer · 2026-Mar-15 The study is a randomized trial in oncology patients but fails key eligibility criteria: it is not explicitly a Phase III trial, lacks a time-to-event primary efficacy endpoint (OS/PFS/etc.), and does not involve a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Eligibility criteria in phase 3 randomized controlled trials in metastatic non-small cell lung cancer. PMID 41838447 · Cancer · 2026-Mar-15 This is a meta-analysis of eligibility criteria across multiple phase 3 RCTs, not an original report of a single trial's efficacy results. It lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. PMID 41817106 · Cancer · 2026-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma. PMID 41808581 · Cancer · 2026-Mar-15 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy. PMID 41808570 · Cancer · 2026-Mar-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Bowel Cleansing with Mini S-Oral Sulfate Tablet versus the Conventional Oral Sulfate Tablet: A Prospective, Randomized, Investigator-Blinded, Multicenter, Noninferior, Phase 3 Trial. PMID 41306094 · Gut Liver · 2026-Mar-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Parotid-Sparing Versus Conventional Whole Brain Radiation Therapy: A Multi-Institutional Randomized Clinical Trial. PMID 41161645 · Int J Radiat Oncol Biol Phys · 2026-Mar-15 The study is a randomized trial in oncology with original results, but it does not meet all required criteria: it lacks a drug-containing intervention (it compares radiotherapy techniques), it has no time-to-event efficacy endpoint (the primary endpoint is xerostomia score), and the phase is not explicitly stated as Phase III/IIIb or II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Total Body Irradiation-Based Versus Chemotherapy-Alone Myleloblative Conditioning Regimen Before Hematopoietic Allogeneic Stem Cell Transplantation in Adults With Acute Lymphoblastic Leukemia: A Multi-Institutional Study From the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). PMID 41135711 · Int J Radiat Oncol Biol Phys · 2026-Mar-15 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Hypofractionated Dose Escalation Versus Conventionally Fractionated Radiation Therapy for Patients With Intermediate- and High-Risk Localized Prostate Cancer: Long-Term Results of the HYPRO Trial. PMID 41106690 · Int J Radiat Oncol Biol Phys · 2026-Mar-15 The report is an original Phase III randomized trial in oncology with human patients and time-to-event endpoints (relapse-free survival, overall survival). However, the intervention is radiation therapy, not a drug-containing intervention. Therefore, it does not meet the criterion of having a drug-containing intervention.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HEBERSaVax immunotherapy combined with first-line chemotherapy in advanced ovarian cancer: Phase II CENTAURO-4 trial results. PMID 41099583 · Int J Cancer · 2026-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
[Comparison of the efficacy and safety of venetoclax plus azacitidine versus D-CAG regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia]. PMID 41991313 · Zhonghua Xue Ye Xue Za Zhi · 2026-Mar-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study. PMID 41830344 · Clin Infect Dis · 2026-Mar-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparative efficacy of neoadjuvant short-course versus long-course radiotherapy-based regimens with or without immunotherapy for locally advanced pMMR rectal cancer: a systematic review and network meta-analysis. PMID 41826948 · BMC Med · 2026-Mar-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial. PMID 41826281 · Nat Commun · 2026-Mar-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial. PMID 41796601 · Lancet · 2026-Mar-14 The trial meets criteria for oncology, human, randomized, Phase III, drug intervention, and original result, but the primary efficacy endpoint is ORR, which is not a time-to-event endpoint as required. No time-to-event signal (Kaplan-Meier, HR, or time-to-event outcome) is identified in the abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis. PMID 41765025 · Lancet · 2026-Mar-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-Term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial. PMID 41833909 · Int J Radiat Oncol Biol Phys · 2026-Mar-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Associations between tumor immune response and prognosis in node-negative breast cancer patients in the randomized DBCG HYPO trial. PMID 41826895 · BMC Cancer · 2026-Mar-13 The study is a randomized trial in oncology reporting a time-to-event endpoint, but it investigates radiotherapy fractionation schedules, not a drug-containing intervention. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. The primary focus is a biomarker/prognostic analysis, not the reporting of a drug's efficacy in a definitive trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone. PMID 41826282 · Pharmacogenomics J · 2026-Mar-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial. PMID 41824255 · J Patient Rep Outcomes · 2026-Mar-13 The study is part of a Phase III randomized trial (CARTITUDE-4) evaluating a drug intervention (ciltacabtagene autoleucel) in oncology (multiple myeloma). However, this specific abstract reports validation of a patient-reported outcome instrument (MySIm-Q) using trial data, not a time-to-event efficacy outcome (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. Therefore, it does not meet the time-to-event efficacy endpoint criterion for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Protocol digest of a randomized phase III study of pola-R-CHP/high-dose methotrexate/IT vs. pola-R-CHP/IT for newly diagnosed diffuse large B-cell lymphoma with high risk of central nervous system relapse: JCOG2201 (PREMIER). PMID 41402979 · Jpn J Clin Oncol · 2026-Mar-13 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
A randomized controlled phase III trial on continued or paused PD-1 pathway blockade for patients with advanced renal cell carcinoma (JCOG1905, STOP study): a study protocol. PMID 41324490 · Jpn J Clin Oncol · 2026-Mar-13 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer. PMID 41826123 · Eur Urol Focus · 2026-Mar-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial. PMID 41819560 · BMJ · 2026-Mar-12 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 8 Panel · risk unclear
The Efficacy and Safety of Enarodustat for the Treatment of Anemia in Hemodialysis-Dependent Chronic Kidney Disease Patients: A Phase 3, Multicenter, Randomized, Active-Comparator (Recombinant Human Erythropoietin), Open-Label Study - The ENARODIAL Study. PMID 41818346 · Am J Nephrol · 2026-Mar-12 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial. PMID 41816796 · Nutr Clin Pract · 2026-Mar-12 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia. PMID 41812193 · N Engl J Med · 2026-Mar-12 The record is a Phase 3 randomized oncology trial with a drug intervention and original results. However, the primary efficacy endpoint is a categorical proportion (odds ratio/risk ratio for absence of chemotherapy modifications), not a time-to-event outcome (OS, PFS, DFS, EFS, RFS, TTP, or any Kaplan-Meier/HR analysis). The deterministic review correctly flagged 'no_time_to_event_signal'. Therefore, it does not meet the time-to-event criterion for this adjudication.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. PMID 41385341 · Blood · 2026-Mar-12 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 4 Panel · risk unclear
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia. PMID 41358601 · N Engl J Med · 2026-Mar-12 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. PMID 41833492 · Eur Urol · 2026-Mar-11 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed